<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36495882</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>401</Volume><Issue>10371</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>139</EndPage><MedlinePgn>131-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(22)02397-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(22)02397-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Type 2 circulating vaccine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading cause of poliomyelitis. A novel type 2 OPV (nOPV2) has been developed to be more genetically stable with similar tolerability and immunogenicity to that of Sabin type 2 vaccines to mitigate the risk of cVDPV2. We aimed to assess these aspects of nOPV2 in poliovirus vaccine-naive newborn infants.</AbstractText><AbstractText Label="METHODS">In this randomised, double-blind, controlled, phase 2 trial we enrolled newborn infants at the Matlab Health Research Centre, Chandpur, Bangladesh. We included infants who were healthy and were a single birth after at least 37 weeks' gestation. Infants were randomly assigned (2:1) to receive either two doses of nOPV2 or placebo, administered at age 0-3 days and at 4 weeks. Exclusion criteria included receipt of rotavirus or any other poliovirus vaccine, any infection or illness at the time of enrolment (vomiting, diarrhoea, or intolerance to liquids), diagnosis or suspicion of any immunodeficiency disorder in the infant or a close family member, or any contraindication for venipuncture. The primary safety outcome was safety and tolerability after one and two doses of nOPV2, given 4 weeks apart in poliovirus vaccine-naive newborn infants and the primary immunogenicity outcome was the seroconversion rate for neutralising antibodies against type 2 poliovirus, measured 28 days after the first and second vaccinations with nOPV2. Study staff recorded solicited and unsolicited adverse events after each dose during daily home visits for 7 days. Poliovirus neutralising antibody responses were measured in sera drawn at birth and at age 4 weeks and 8 weeks. This study is registered on ClinicalTrials.gov, NCT04693286.</AbstractText><AbstractText Label="FINDINGS">Between Sept 21, 2020, and Aug 16, 2021, we screened 334 newborn infants, of whom three (&lt;1%) were found to be ineligible and one (&lt;1%) was withdrawn by the parents; the remaining 330 (99%) infants were assigned to receive nOPV2 (n=220 [67%]) or placebo (n=110 [33%]). nOPV2 was well tolerated; 154 (70%) of 220 newborn infants in the nOPV2 group and 78 (71%) of 110 in the placebo group had solicited adverse events, which were all mild or moderate in severity. Severe unsolicited adverse events in 11 (5%) vaccine recipients and five (5%) placebo recipients were considered unrelated to vaccination. 306 (93%) of 330 infants had seroprotective maternal antibodies against type 2 poliovirus at birth, decreasing to 58 (56%) of 104 in the placebo group at 8 weeks. In the nOPV2 group 196 (90%) of 217 infants seroconverted by week 8 after two doses, when 214 (99%) had seroprotective antibodies.</AbstractText><AbstractText Label="INTERPRETATION">nOPV2 was well tolerated and immunogenic in newborn infants, with two doses, at birth and 4 weeks, resulting in almost 99% of infants having protective neutralising antibodies.</AbstractText><AbstractText Label="FUNDING">Bill &amp; Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Khaelqu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Chandpur, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, WA, USA. Electronic address: ananda.bandyopadhyay@gatesfoundation.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoque</LastName><ForeName>Masuma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Chandpur, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gast</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunus</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Chandpur, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>Khondoker M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>National Polio and Measles Laboratory, Institute of Public Health, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendley</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Annelet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Research in Infectious Diseases, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Sue Ann Costa</ForeName><Initials>SAC</Initials><AffiliationInfo><Affiliation>Global Research in Infectious Diseases, Rio de Janeiro, Brazil; Department of Paediatrics, Oxford University, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Allen G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Chandpur, Bangladesh; Rural Health Research Institute, Charles Sturt University, Wagga Wagga, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>International Centre for Diarrhoeal Disease Research, Chandpur, Bangladesh; International Vaccine Institute, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tritama</LastName><ForeName>Erman</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>PT Bio Farma, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04693286</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2023 Jan 14;401(10371):83-85. doi: 10.1016/S0140-6736(22)02455-2</RefSource><PMID Version="1">36495877</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests ET is a full-time employee of the vaccine manufacturer, PT Bio Farma (Bandung, Indonesia). All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36495882</ArticleId><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)02397-2</ArticleId><ArticleId IdType="pii">S0140-6736(22)02397-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283&#x2013;S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine&#x2014;worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H. Why have cVDPV2 outbreaks increased globally after the polio immunization strategy switch: challenges for the polio eradication endgame. China CDC Wkly. 2020;2:176&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393165</ArticleId><ArticleId IdType="pubmed">34594619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Modlin JF, Wenger J, Gast C. Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review. Clin Infect Dis. 2018;67(suppl 1):S35&#x2013;S41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206125</ArticleId><ArticleId IdType="pubmed">30376081</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Zipursky A. A novel tool to eradicate an ancient scourge: the nOPV2 story. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00582-5. published online Sept 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00582-5</ArticleId><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Polio-free certification: WHO South-East Asia. World Health Organization. https://www.who.int/southeastasia/activities/maintaining-polio-free-status/polio-free-certification-who-south-east-asia</Citation></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736&#x2013;751.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. In: Poliovirus: methods in molecular biology. Mart&#xed;n J, editor. Humana Press; New York: 2016. Standardized methods for detection of poliovirus antibodies; pp. 145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Asturias EJ, O'Ryan M, et al. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine. 2017;35:7283&#x2013;7291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5725506</ArticleId><ArticleId IdType="pubmed">29150209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376:1682&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast C, Bandyopadhyay AS, S&#xe1;ez-Llorens X, et al. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. J Infect Dis. 2021;5:852&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledinko N, Melnick JL. Interference between poliomyelitis viruses in tissue culture. J Exp Med. 1954;100:247&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2136376</ArticleId><ArticleId IdType="pubmed">13192251</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado YA, Pe&#xf1;a-Cruz V, de la Luz Sanchez M, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis. 1997;175:545&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110245</ArticleId><ArticleId IdType="pubmed">9041324</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Vaccine-derived poliovirus type 2 (VDPV2) detected in environmental samples in London, UK, World Health Organization. June 20, 2022. https://www.who.int/news/item/22-06-2022-vaccine-derived-poliovirus-type-2-(vdpv2)-detected-in-environmental-samples-in-london--uk</Citation></Reference><Reference><Citation>Shulman LM, Gavrilin E, Jorba J, et al. Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. Euro Surveill. 2014;19:20709.</Citation><ArticleIdList><ArticleId IdType="pubmed">24576471</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater&#x2014;New York, June&#x2013;August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1065&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill M, Bandyopadhyay AS, Pollard AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet. 2022;400:713&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">35988575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateen FJ, Shinohara RT, Sutter RW. Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine. 2013;31:2517&#x2013;2524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979583</ArticleId><ArticleId IdType="pubmed">22728224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>